MRK - Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

2024-04-19 13:49:43 ET

Summary

• SELLAS Life Sciences Group, Inc. is a late-stage biotech company with a leading drug candidate, Galinpepimut-S, or GPS, that has a 44% probability of success and a potential 9x return.
• GPS is an immunotherapy drug targeting the Wilms Tumor 1 antigen, which is overexpressed in AML patients. The AML market size is estimated to be $3.1 billion.
• The upcoming interim readout of the GPS phase 3 clinical trial in April could significantly impact the valuation of the drug, with a successful trial potentially increasing its value to $1.5B.

SELLAS Life Sciences Group, Inc. ( SLS ) is a late-stage biotech company offering us a GPS lottery ticket with an estimated 9x return and 44% probability of success. The ticket is time-sensitive, as their leading drug candidate Galinpepimut-S ((GPS)) phase 3 clinical trial interim report is scheduled to be read out in the upcoming days/weeks....

For further details see: